Ian Hickson

Professor of Drug Discovery Bioscience

Newcastle University

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom Professors in Cancer Biology Cancer Biology professors in United Kingdom

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (9)

Year:

2023

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Collaborators (7)

Jennie Jeyapalan

Assistant Professor

University of Nottingham

UNITED KINGDOM

View details

Alec Paschalis

Institute of Cancer Research

UNITED KINGDOM

View details

Celine Cano

Reader in Medicinal Chemistry

Newcastle University

UNITED KINGDOM

View details

Luke Gaughan

Reader in Molecular Oncology

Newcastle University

UNITED KINGDOM

View details

Steve Wedge

Newcastle University

UNITED KINGDOM

View details

Elaine Willmore

Newcastle University

UNITED KINGDOM

View details

Jane Endicott

Prof of Cancer Structural Biology

Newcastle University

UNITED KINGDOM

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Ian Hickson

Research Interests

Explore related searches

Contact this professor

Articles (9)

The catalytic subunit of DNA-PK regulates transcription and splicing of AR in advanced prostate cancer

Targeting Mre11 overcomes platinum resistance and induces synthetic lethality in XRCC1 deficient epithelial ovarian cancers.

An Alkynylpyrimidine-Based Covalent Inhibitor That Targets a Unique Cysteine in NF-κB-Inducing Kinase

Spirocyclic Thiohydantoin Antagonists of F877L and Wild-Type Androgen Receptor for Castration-Resistant Prostate Cancer

FEN1 Blockade for Platinum Chemo-Sensitization and Synthetic Lethality in Epithelial Ovarian Cancers

Discovery of JNJ-63576253, a next-generation androgen receptor antagonist active against wild-type and clinically-relevant ligand binding domain mutations in mCRPC.

Discovery of JNJ-63576253, a Next-Generation Androgen Receptor Antagonist Active Against Wild-Type and Clinically Relevant Ligand Binding Domain Mutations in Metastatic Castration-Resistant Prostate Cancer

Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC).

Modulating Androgen Receptor-Driven Transcription in Prostate Cancer with Selective CDK9 Inhibitors

Collaborators (7)

Jennie Jeyapalan

Alec Paschalis

Celine Cano

Luke Gaughan

Steve Wedge

Elaine Willmore

Jane Endicott

Make your next move.